BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28846953)

  • 1. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
    Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
    Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
    Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
    Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of WT1 expression on the prognosis of allogeneic hematopoietic stem cell transplantation in acute leukemia].
    Jiang BQ; Luo Y; Zhao YM; Tan YM; Yu J; Lai XY; Zhu YY; Sun J; Zheng WY; He JS; Wei GQ; Cai Z; Huang H; Shi JM
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):989-993. PubMed ID: 30612399
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
    Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
    [No Abstract]   [Full Text] [Related]  

  • 18. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
    Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
    Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T
    Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
    Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.